CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3 mutated AML
   Google Scholar   
Citation:
J Clin Oncol vol 29 (supplement) abstr TPS199
Meeting Instance:
ASCO 2011
Year:
2011
Type:
Abstract
Sub type:
Poster General
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Preliminary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
2567  
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                     
Networks:
 
Study
CALGB-10603
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: